SQZ APCs: Oncology

COMMERCIALIZATION RIGHTS:

SQZ-PBMC-HPV
HPV+ Solid Tumors

Phase 1
NCT04084951

SQZ-PBMC-X
Solid Tumors

Pre-clinical

Next Gen SQZ APC
Solid and Liquid Tumors

Pre-clinical

SQZ APCs: Infectious Disease

COMMERCIALIZATION RIGHTS:

SQZ-ID1
Chronic Infectious Disease

Pre-clinical

SQZ-RRV
Rapid Response Vaccines

Pre-clinical

SQZ AACs: Oncology

COMMERCIALIZATION RIGHTS:

SQZ-AAC-HPV
HPV+ Solid Tumors

Pre-clinical

SQZ-AAC-KRAS
KRAS mut Solid Tumors

Pre-clinical

Next Gen SQZ AAC
Solid and Liquid Tumors

Pre-clinical

SQZ TACs: Immune Tolerance

COMMERCIALIZATION RIGHTS:

SQZ-TAC-AAV
Gene Therapy Repeat Dosing

Pre-clinical

SQZ-TAC-T1D
Type 1 Diabetes

Pre-clinical

Next Gen SQZ TACs
Multiple Diseases

Pre-clinical

We and AskBio entered into a collaboration in 2019 to research the use of SQZ TACs to enable repeat dosing of gene therapies.
The JDRF T1D Fund has invested in SQZ Biotech on multiple occasions to help progress the T1D program.